Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

EFFECT A European Training Program to Foster the Full Therapeutic Potential of Antisense Technology across Tissues

Coordinator
Stichting Radboud Universitair Medisch Centrum, Netherlands
Runs
1 January 2025 to 31 December 2028
Status
Running
EU funding
€3.0m
Total cost
—
Partners
20 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101168372

What the project is doing

In the project's own words, from its summary on CORDIS.

The EFFecT Doctoral Training (DN) Network responds to the evolving landscape of RNA-based therapeutics and in particular antisense oligonucleotides (ASO). Over the last 25 years, only 21 antisense nucleic acid-based molecules have been approved by the FDA or/and EMA. However, the field is now at the tipping point of maturity to achieve regular translation from bench to bed side, provided that certain obstacles are successfully addressed.

Our consortium involves experts from academia, industry, and non-profit organizations across nine European countries with first-hand experience in the successful translation of this new technology and in-depth knowledge of the remaining hurdles for its success. With leading scientists at different career stages, EFFecT’s core is form by nine academic and three industrial partners. EFFecT's objectives include addressing tissue-specific delivery challenges, imparting knowledge on diverse ASO modalities, and creating a roadmap for ASO therapeutics in Europe.

The network's composition leverages over 20 years of experience in nucleic acid drug development, and was born from the successful COST Action ""Delivery of Antisense RNA ThERapeutics"" (DARTER). The EFFecT training network ensures a comprehensive education for Doctoral Candidates through knowledge exchange, secondments, research workshops and dissemination. This network is expanded with the collaborations of experts in communication, intellectual property, and open science that will train the DCs in good scientific practices.

By addressing training gaps and fostering collaborations, EFFecT is poised to deliver the next generation of experts in this up-and coming field, elevating Europe's visibility and competitiveness in antisense RNA therapeutics.""

Who is involved

OrganisationCityCountryRole
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsCoordinator
Universiteit GentGentBelgiumParticipant
Asociacion Instituto De Investigacion Sanitaria BiobizkaiaBarakaldo BizkaiaSpainParticipant
Universidad Autonoma De MadridMadridSpainParticipant
Universidad Del Pais Vasco/ Euskal Herriko UnibertsitateaLeioaSpainAssociatedpartner
Institut Servier D'innovation TherapeutiqueGif-Sur-YvetteFranceParticipant
Universite De Versailles Saint-Quentin En YvelinesVersaillesFranceParticipant
Universite Paris-SaclayGif-Sur-YvetteFranceAssociatedpartner
Fondazione Hub Innovazione TrentinoTrentoItalyAssociatedpartner
Universita Degli Studi Di TrentoTrentoItalyParticipant
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
Astherna BVNijmegenNetherlandsParticipant
Stichting Duchenne Data FoundationSoestNetherlandsAssociatedpartner
Stichting Radboud UniversiteitNijmegenNetherlandsAssociatedpartner
Stichting Dutch Antisense TherapeuticsGroningenNetherlandsAssociatedpartner
Iceta Instituto De Ciencias, Tecnologias E Agroambiente Da Universidade Do PortoPortoPortugalParticipant
Universidade Do PortoPortoPortugalAssociatedpartner
Astrazeneca ABSodertaeljeSwedenParticipant
Karolinska InstitutetStockholmSwedenAssociatedpartner
University College LondonLondonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI